ArticleInternational journal of cardiology. Cardiovascular risk and prevention2025
Hypertension and lung cancer in China (2002-2019): A nationwide study of temporal trends, demographic disparities, and independent risk associations.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Temporal trends and forecasted mortality involving lung cancer with co-listed hypertension in U.S. adults, 2000-2035.Cardio-oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence suggests a potential link between hypertension and cancer, yet the relationship between elevated blood pressure and lung cancer risk remains underexplored, particularly in large, population-based settings. Objective: To investigate temporal trends in hypertension prevalence among lung cancer patients and to assess whether hypertension is independently associated with lung cancer risk in the Chinese adult population. Methods: We analyzed data from 2,745,893 adults aged ≥18 years who participated in the China Chronic Disease and Risk Factor Surveillance (CCDRFS) program from 2002 to 2019. Trends in hypertension prevalence among lung cancer patients were assessed across demographic strata. Multivariable logistic regression models adjusted for age, sex, smoking, obesity, and region were used to estimate adjusted odds ratios (aORs) for lung cancer associated with hypertension. Results: Among 168,427 lung cancer patients (6.1 % of total), 58.3 % had coexisting hypertension. Hypertension prevalence among lung cancer patients rose from 47.2 % in 2002 to 62.8 % in 2019, with sharper increases in rural (49.3 %-66.1 %) and western regions (50.4 %-66.9 %). After adjustment, hypertension was independently associated with lung cancer (aOR = 1.37; 95 % CI: 1.31-1.43), with stronger associations observed in females (aOR = 1.49), individuals aged ≥60 years (aOR = 1.54), non-smokers (aOR = 1.44), and obese participants (aOR = 1.46). Conclusions: Hypertension is highly prevalent among lung cancer patients in China and appears to be independently associated with increased lung cancer risk. These findings suggest the need for integrated cardio-oncology surveillance and prevention strategies, particularly for high-risk subpopulations such as older adults, women, and non-smokers. Further prospective studies are warranted to explore the mechanisms underlying this association and to evaluate whether hypertension control may influence lung cancer burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.